Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Mengdan Liu, Ming Yan, Amanda G. Davis, Samuel A. Stoner, Edward D. Ball, Dong-Er Zhang

Blood Neoplasia (2025) 2 (3): 100107.

https://doi.org/10.1016/j.bneo.2025.100107

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival

Blood Neoplasia (2025) 2 (3): 100085.

https://doi.org/10.1016/j.bneo.2025.100085

Published: 2025

Includes: Supplemental data

Journal Articles

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

Rose Laflamme, Véronique Lisi, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Vincent-Philippe Lavallée, Guillaume Lettre

Blood Neoplasia (2025) 2 (3): 100118.

https://doi.org/10.1016/j.bneo.2025.100118

Published: 2025

Includes: Supplemental data

Journal Articles

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng, Kala Hayes, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Shuko Nojiri, Yasushi Okazaki, Michael Andreeff, Marina Konopleva, Yoko Tabe

Blood Neoplasia (2025) 2 (3): 100121.

https://doi.org/10.1016/j.bneo.2025.100121

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only